- Report
- October 2024
- 191 Pages
Global
From €3339EUR$3,545USD£2,856GBP
€3710EUR$3,939USD£3,173GBP
- Report
- May 2024
- 131 Pages
Global
From €6122EUR$6,499USD£5,235GBP
- Report
- June 2024
- 200 Pages
Global
From €7489EUR$7,950USD£6,404GBP
- Report
- January 2022
- 60 Pages
Global
From €3721EUR$3,950USD£3,182GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1884EUR$2,000USD£1,611GBP
- Report
- February 2024
- 94 Pages
Global
From €3500EUR$3,980USD£3,098GBP
- Report
- May 2022
- 56 Pages
Global
From €1884EUR$2,000USD£1,611GBP
Ependymoma is a type of cancer that affects the central nervous system. It is a rare form of cancer, but it is the third most common type of brain tumor in children. Treatment for ependymoma typically involves surgery, radiation therapy, and chemotherapy. Drugs used to treat ependymoma are typically part of the larger Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological conditions, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy.
The CNS drug market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the CNS drug market include Pfizer, Novartis, Merck, GlaxoSmithKline, and Johnson & Johnson. Other companies, such as AbbVie, Bristol-Myers Squibb, and Eli Lilly, also have a presence in the CNS drug market. Show Less Read more